Biotech Archives - Page 45 of 795

2 minute read

Rhythm Pharmaceuticals Presents Data From Phase 3 Pediatrics Trial At Pediatric Endocrine Society Annual Meeting

May 6, 8:15 AM

-- Oral presentation showcased previously disclosed data that demonstrate setmelanotide achieved 3.04 mean reduction in BMI-Z score and 18.4 percent mean reduction in BMI in 12 patients ages 2-<6yo with obesity due to

RYTM

1 minute read

RTX’s Advanced Ground System For Space-based Missile Warning Now Operational

By Benzinga Newsdesk

May 6, 8:14 AM

Mission data processing framework rapidly moved from prototype to operations at Battlespace Awareness CenterAURORA, Colo., May 6, 2024 /PRNewswire/ -- An advanced ground system for space-based missile warning developed

RTX

2 minute read

Edgewise Therapeutics Doses First Patient In Phase 2 CIRRUS-HCM Trial Of EDG-7500 In Obstructive Hypertrophic Cardiomyopathy

By Benzinga Newsdesk

May 6, 8:12 AM

Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced the dosing of the first patient in the Phase 2 CIRRUS-HCMtrial of EDG-7500. EDG-7500 is a novel oral,

EWTX

4 minute read

Lineage Cell Therapeutics Announces OpRegen Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured At 2024 Retinal Cell & Gene Therapy Innovation Summit

By Benzinga Newsdesk

May 6, 8:04 AM

BCVA gains of +5.5 letters at 24 months in Cohort 4 patients (n=10)BCVA gains of +7.4 letters among Cohort 4 patients with extensive OpRegen bleb coverage of the GA lesion (n=5)Maintenance or increases in external

LCTX

3 minute read

Lyra Therapeutics Reports Topline Results From Phase 3 ENLIGHTEN 1 Trial For LYR-210 in Chronic Rhinosinusitis; ENLIGHTEN 1 Trial Did Not Meet Its Primary Endpoint; Company Plans To Evaluate Full Dataset And Path Forward

By Benzinga Newsdesk

May 6, 8:01 AM

ENLIGHTEN 1 trial did not meet its primary endpoint Company plans to evaluate full dataset and path forwardWATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA) ("Lyra" or the

LYRA

2 minute read

Cathie Wood’s Ark Invest Snaps Up $3.54M Worth Of Shares In This Biopharma Company Following Positive Obesity Pipeline Update

By Shanthi Rexaline

May 5, 3:16 PM

As the demand for obesity drugs continues to surge, biopharma companies are eagerly seizing the opportunity to capitalize on the trend.

AMGN

2 minute read

Newly Listed Migraine-Focused AEON Biopharma Stock Plunges On Friday – Read Here Why

By Vandana Singh

May 3, 1:11 PM

Preliminary results of AEON Biopharma's Phase 2 trial for chronic migraine treatment reveal no significant improvement over placebo. Despite anticipated reductions in monthly migraine days, statistical significance was not reached, prompting a review of development strategies and financial measures.

AEON

7 minute read

Johnson & Johnson Announces Phase 2 Data For ERLEADA Plus Androgen Deprivation Therapy Following Radical Prostatectomy In Patients With High-Risk Localized Prostate Cancer Show 100% Biochemical Free Recurrence Rate More Than Two Years Post-Surgery; Stu…

By Benzinga Newsdesk

May 3, 12:23 PM

Study highlights opportunity for treatment intensification in this population since approximately 50% of patients with high-risk localized prostate cancer (HRLPC) experience disease recurrence within two years of

JNJ

2 minute read

Serum Institute of India Inks Large-Scale Supply Deal For BCG Use In ImmunityBio’s Bladder Cancer Combo Therapy

By Vandana Singh

May 3, 12:19 PM

Unlocking global access to Bacillus Calmette-Guerin (BCG) for cancer therapy. ImmunityBio partners with Serum Institute to expand BCG supply. FDA-approved Anktiva plus BCG for bladder cancer.

IBRX

3 minute read

CG Oncology Announces Data From The Phase 3 BOND-003 Study Evaluating The Efficacy And Safety Of Cretostimogene Monotherapy, Demonstrated 75.2% Complete Response Rate In High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

By Benzinga Newsdesk

May 3, 11:26 AM

- Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today at 4:30pm EDT

CGON